The assessment of inflammation markers IL-1beta and IL-6 before and after FMT in patients with Parkinson’s disease. (P3-11.008)

Abstract

<h3>Objective:</h3> The objective of this study is to investigate how fecal microbiota transplant affects plasma inflammatory marker levels in Parkinson’s disease patients. <h3>Background:</h3> Parkinson’s disease has a possible origin in the intestinal nervous system. However, the precise mechanism of how it spreads to the brain has not yet been fully explained. In recent years, gut inflammation in Parkinson disease patients has become a topic of interest. This inflammation may be influenced by the microbiota present in the large intestine. Altering intestinal microbiota with FMT may have a crucial effect on the level of gut inflammation in Parkinson’s disease patients. <h3>Design/Methods:</h3> The aim of our study is to assess the change of IL-1beta and IL-6, which are markers of inflammation, before and after FMT treatment in Parkinson’s disease patients. Our study includes 20 patients, 13 males and 7 females, with the mean age of 61.9 (+/−7,9). These patients were randomized into either the FMT group or auto-FMT group. The microbiota transplant was performed via colonoscopy. The plasma samples were collected both before and 3 months after FMT treatment. The analysis was performed using the ELISA method. Student’s t-test will be used to compare the outcomes. <h3>Results:</h3> The results will determine whether FMT modulates levels of inflammatory markers in plasma of PD patients. <h3>Conclusions:</h3> Fecal microbiota transplant is a potential treatment method for Parkinson’s disease. Preliminary studies have shown that it is a safe method of modulating inflammation in PD patients. The data on inflammatory marker levels before and after this procedure are currently being analyzed. <b>Disclosure:</b> Mr. Sadowski has nothing to disclose. The institution of Dr. Figura has received research support from Medical University of Warsaw. The institution of Dr. Figura has received research support from Biocodex. Dr. Milanowski has nothing to disclose. Dariusz Koziorowski has received personal compensation for serving as an employee of Medical University of Warsaw. The institution of Dariusz Koziorowski has received research support from BIOCODEX MICROBIOTA FUNDATION. Dr. Szlufik has nothing to disclose. Miss Antoniak has nothing to disclose. Miss Nowak has nothing to disclose. Mr. Kopczynski has nothing to disclose. Ms. Grzyb has nothing to disclose.